Grail Stock

grail.comHealthcareFounded: 2016Funding to Date: $2.02B

GRAIL is a healthcare company specializing in early cancer detection by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to developed a multi-cancer early detection blood test.

Register for Details

For more details on financing and valuation for Grail, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Grail.

Register Today

Grail investors also invested in these private companies


Management Team

Gautam Kollu
Chief Commercial Officer
Matthew Young
Chief Financial Officer & Chief Operating Officer
Aaron Freidin
Chief Financial Officer

Board Members

Brook Byers Ph.D
Maykin Ho Ph.D
Robert Nelsen
ARCH Venture Partners
Xiangmin Cui Ph.D
Decheng Capital
Catherine Friedman
Kaye Foster
William Rastetter Ph.D
Richard Klausner MD

Other companies like Grail in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


The health plan provider will make testing available to its own employees, followed by its approximately 2.2 million commercial members.
Caris said it has already provided materials to Illumina and should not have to indulge a "fishing expedition for irrelevant, highly sensitive details."
The measures are legally binding for both Illumina and Grail, and compliance with them will be monitored by a trustee to be approved by the commission.